Journal
TRENDS IN IMMUNOLOGY
Volume 43, Issue 5, Pages 379-390Publisher
CELL PRESS
DOI: 10.1016/j.it.2022.03.003
Keywords
-
Categories
Funding
- Princess Margaret Cancer Foundation
- Ontario Institute for Cancer Research
- Terry Fox Research Institute
- Senior Investigator Award from the Ontario Institute for Cancer Research
- Canada Research Chair in Translational Genomics
- Gattuso-Slaight Personalized Cancer Medicine Fund at the Princess Margaret Cancer Centre
- BMO Chair in Precision Cancer Genomics
- Hold'em for Life Oncology Fellowship (University of Toronto)
Ask authors/readers for more resources
The cancer research community is searching for more biomarkers of response and resistance to immune checkpoint treatment, and analyzing the loss of the 9p21.3 locus may provide additional knowledge about immune evasion in cancer.
The cancer research community continues to search for additional biomarkers of response and resistance to immune checkpoint treatment (ICT). The ultimate goal is to direct the use of ICT in patients whose tumors are most likely to benefit to achieve a refinement that is equivalent to that of a genotype-matched targeted treatment. Dissecting the mechanisms of ICT resistance can help us characterize ICT nonresponders more efficiently. In this opinion, we argue that there may be additional knowledge gained about immune evasion in cancer by analyzing the loss of the human 9p21.3 locus; as an example, we highlight findings of 9p21.3 loss from the investigator-initiated, pan-cancer INSPIRE study, in which patients were treated with pembrolizumab (anti-PD-1 antibody) ICT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
